Novo Nordisk lowers Ozempic cost to $499 per month for uninsured U.S. patients, expanding access through NovoCare and 70,000 ...

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...

Novo Nordisk (NYSE: NVO) stock is up 2.2% through 10:30 a.m. ET on Viking's bad news. Where to invest $1,000 right now? Our ...

Novo Nordisk share price rose nearly 5% on August 18, 2025. The hike came after the US Food and Drug Administration granted ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

Novo said cash-paying Americans can now buy Ozempic for $499 per month through various channels including its official ...

While Novo Nordisk say they're fighting against stigma, critics say they could be promoting prescription drugs under the ...

Novo Nordisk revealed on Monday that US patients can now receive a month’s supply of Ozempic, a highly effective diabetes ...

The string of negative updates from Novo Nordisk and positive news flow from the main competitor Eli Lilly has finally ended ...

Expanded approval of Wegovy was based on results from the Phase III ESSENCE trial (NCT04822181), which demonstrated ...

Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to ...

Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.